Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076971 | 0.87 | GRIN1 (0.34) | TRPV4SMN1; SMN2HPGDPDE4A | |
| SCHEMBL4079858 | 0.87 | TRPV4 (0.37) | TRPV4SMN1; SMN2HPGDGAAADRA1A | |
| SCHEMBL4069880 | 0.84 | HPGD (0.47) | TRPV4SMN1; SMN2HPGDPDE4A | |
| SCHEMBL5208670 | 0.77 | TRPV4 (0.40) | TRPV4SMN1; SMN2HPGDGAA | |
| SCHEMBL4079859 | 0.70 | ATP4A (0.40) | TRPV4GAAMAPT | |
| SCHEMBL4076975 | 0.70 | ATP4A (0.38) | TRPV4SMN1; SMN2HPGDGAA | |
| SCHEMBL4847783 | 0.70 | ALDH1A1 (0.40) | SMN1; SMN2GAAPDE4AMAPT | |
| SCHEMBL4069883 | 0.68 | HPGD (0.49) | TRPV4SMN1; SMN2HPGDPDE4A | |
| SCHEMBL1877935 | 0.67 | NOS3 (0.42) | TRPV4SMN1; SMN2ROCK1ADRA1AMAPT | |
| SCHEMBL4072241 | 0.67 | KDM4E (0.36) | GAAPDE4AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556372-B1 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060094878-A1 | Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094878-A1 | Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | CHRM4, CHRM3, CHRM1 | TRPV4 204/4885SMN1; SMN2 3015/4885HPGD 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.